Filtered By:
Drug: Eloxatin
Therapy: Chemotherapy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 22 results found since Jan 2013.
In vitro siRNA-mediated GPX4 and AKT1 silencing in oxaliplatin resistance cancer cells induces ferroptosis and apoptosis
AbstractOxaliplatin is a member of platinum-based chemotherapy drugs frequently used in colorectal cancer (CRC). However, resistance to oxaliplatin causes tumor progression and metastasis.Akt1 andGpx4 are essential regulator genes of apoptosis and ferroptosis pathways. Inhibition of these genes might eradicate oxaliplatin resistance in resistant CRC cells. We compared two cell death strategies to reverse drug resistance in Caco-2 and HT-29 oxaliplatin-resistant cell lines. We used theAKT1-specific siRNA to induce apoptosis. Also,GPX4-specific siRNA and FIN56 were utilized to generate ferroptosis. The effect of these treatm...
Source: Medical Oncology - August 26, 2023 Category: Cancer & Oncology Source Type: research
POU2F1/DNMT3a Pathway Participates in Neuropathic Pain by Hypermethylation-Mediated LRFN4 Downregulation Following Oxaliplatin Treatment
Neurochem Res. 2023 Aug 18. doi: 10.1007/s11064-023-04011-w. Online ahead of print.ABSTRACTEvidence demonstrates that DNA methylation is associated with the occurrence and development of various neurological diseases. However, the potential target genes undergoing DNA methylation, as well as their involvement in the chemotherapy drug oxaliplatin-induced neuropathic pain, are still unclear. Here, Lrfn4, which showed hypermethylation in the promoter regions, was screened from the SRA methylation database (PRJNA587622) following oxaliplatin treatment. MeDIP and qPCR assays identified that oxaliplatin treatment increased the m...
Source: Neurochemical Research - August 17, 2023 Category: Neuroscience Authors: Yan-Hui Gu Jing Wang Wei-Cheng Lu Yong Cheng Rong Tao Shi-Jia Zhang Ting Xu Ke-Wei Zhai Su-Xia Luo Wen-Jun Xin Source Type: research
Reduction of SIRT1-Mediated Epigenetic Upregulation of Nav1.7 Contributes to Oxaliplatin-Induced Neuropathic Pain
CONCLUSIONS: These findings suggest that reduction of SIRT1-mediated epigenetic upregulation of Nav1.7 in the DRG contributes to the development of oxaliplatin-induced neuropathic pain in rats. The intrathecal drug delivery treatment of activating SIRT1 might be a novel therapeutic option for oxaliplatin-induced neuropathic pain.PMID:37192244
Source: Pain Physician - May 16, 2023 Category: Anesthesiology Authors: Ling-Jun Xu Jing Wang Gui-Dan Li Kai-Feng Shen Xing-Hui He Wei Wu Cui-Cui Liu Source Type: research
siRNA-E6 sensitizes HPV-16-related cervical cancer through Oxaliplatin: an in vitro study on anti-cancer combination therapy
ConclusionInhibition of E6 oncogene expression and subsequent E6-siRNA with Oxaliplatin combination therapy could be a novel strategy for cervical cancer treatment.Graphical Abstract
Source: European Journal of Medical Research - January 21, 2023 Category: Research Source Type: research
Precision medicine-guided co-delivery of ASPN siRNA and oxaliplatin by nanoparticles to overcome chemoresistance of colorectal cancer
This study uncovered the critical role of ASPN in causing OXA resistance in CRC patients and suggests a promising nanoformulation that may be more effective than current standard-of-care medications.PMID:36228517 | DOI:10.1016/j.biomaterials.2022.121827
Source: Biomaterials - October 13, 2022 Category: Materials Science Authors: Cheng-Zhi Huang Yue Zhou Qi-Song Tong Qi-Jia Duan Qing Zhang Jin-Zhi Du Xue-Qing Yao Source Type: research
ASAP Nanodrugs Incorporating LDHA siRNA Inhibit M2-like Polarization of TAMs and Amplify Autophagy to Assist Oxaliplatin Chemotherapy against Colorectal Cancer
ACS Applied Materials& InterfacesDOI: 10.1021/acsami.2c05841
Source: ACS Applied Materials and Interfaces - July 7, 2022 Category: Materials Science Authors: Lijun Hu, Sicong Huang, Gengjia Chen, Bo Li, Tan Li, Minzhao Lin, Yongquan Huang, Zecong Xiao, Xintao Shuai, and Zhongzhen Su Source Type: research
Effective Delivery of siRNA-Loaded Nanoparticles for Overcoming Oxaliplatin Resistance in Colorectal Cancer
Chemotherapy resistance represents a formidable obstacle in advanced or metastatic colorectal cancer (CRC) patients. It is reported that ATPase copper transporting alpha (ATP7A) plays an important role in chemotherapy resistance in CRC. Here, we identified ATP7A as a potentially key gene of OXA resistance in CRC. The patients with higher expression of ATP7A tended to have platinum drug resistance. While the lower expression of ATP7A by siRNA knockdown resulted in enhancement of OXA sensitivity and increased OXA-induced apoptosis. Further, we demonstrated a novel and safe strategy to increase CRC chemosensitivity by deliver...
Source: Frontiers in Oncology - February 21, 2022 Category: Cancer & Oncology Source Type: research
CD44 expression enhances chemoresistance and implies occult micrometastases after conversion hepatectomy for initially unresectable colorectal liver metastases.
CONCLUSIONS: CD44 enhances chemoresistance in response to anti-cancer drugs (fluorouracil and oxaliplatin) in colon cancer cells. CD44 expression in liver metastases after chemotherapy implies the presence of occult micrometastases and is a worse prognostic factor in patients with conversion hepatectomy for initially unresectable colorectal liver metastases.
PMID: 33042471 [PubMed]
Source: American Journal of Translational Research - October 13, 2020 Category: Research Tags: Am J Transl Res Source Type: research
Overexpression of CASC11 in ovarian squamous cell carcinoma mediates the development of cancer cell resistance to chemotherapy.
Abstract
LncRNA CASC11 promotes gastric cancer and colon cancer. Our study analyzed the role of CASC11 in ovarian squamous cell carcinoma (OSCC). In the present study we showed that plasma CASC11 was upregulated in OSCC, and the upregulation of CASC11 distinguished OSCC patients from control group. Plasma levels of CASC11 were further increased after chemotherapy. Treatment with oxaliplatin, tetraplatin, cisplatin, and carboplatin mediated the upregulation of CASC11 in cells of OSCC cell line. In addition, overexpression of CASC11 led to increased cancer cell viability under oxaliplatin, tetraplatin, cisplatin, an...
Source: Gene - June 6, 2019 Category: Genetics & Stem Cells Authors: Shen F, Feng L, Zhou J, Zhang H, Xu Y, Jiang R, Zhang H, Chen Y Tags: Gene Source Type: research
A Study on Effect of Oxaliplatin in MicroRNA Expression in Human Colon Cancer
This study outlines the regulatory effects of oxaliplatin on miRNAs expression in colon cancer cells and correlates it with the changing microRNA expression with p53 and p73 expression status in cells. HCT116p53+/+ and HCT116p53-/- cells were exposed to oxaliplatin, and the cellular viability was determined by XTT. p73 was knocked down using siRNA and the tumor cells were then treated with oxaliplatin. The expression profile of 384 miRNAs was determined by TaqMan® human miRNA array and calculated by the ∆∆Ct method. Cellular viability was found to decrease after the treatment with oxaliplatin in a dose-dep...
Source: Journal of Cancer - June 20, 2018 Category: Cancer & Oncology Authors: Jasmine Evert, Surajit Pathak, Xiao-Feng Sun, Hong Zhang Tags: Research Paper Source Type: research
Abstract C5: FLIP protein-protein interaction inhibitors enhance sensitivity of colorectal cancer cells to chemotherapy and TRAIL
ConclusionWe have developed inhibitors of FLIP that decrease its recruitment to the TRAIL-R2 DISC and increase TRAIL-induced caspase activation and apoptosis. Moreover, these inhibitors synergise with 5-Fluorouracil, oxaliplatin and SN38, suggesting that this novel class of agents has therapeutic potential in CRC when used in conjunction with standard-of-care chemotherapeutic agents.AcknowledgementsThis work was supported by a Seeding Drug Discovery award from the Wellcome Trust (reference: 099470).Citation Format: Jennifer P. Fox, Joanna Majkut, Catherine Higgins, Zsuzsanna Nemeth, Adnan Malik, Christopher J. Scott, Peter...
Source: Molecular Cancer Therapeutics - January 7, 2016 Category: Cancer & Oncology Authors: Fox, J. P., Majkut, J., Higgins, C., Nemeth, Z., Malik, A., Scott, C. J., Blurton, P., Boffey, R. J., Perrior, T. R., Harrison, T., Longley, D. B. Tags: Apoptosis, Necrosis, and Autophagy: Poster Presentations - Proffered Abstracts Source Type: research
siRNA-mediated silencing of MDR1 reverses the resistance to oxaliplatin in SW480/OxR colon cancer cells.
Authors: Montazami N, Kheir Andish M, Majidi J, Yousefi M, Yousefi B, Mohamadnejad L, Shanebandi D, Estiar MA, Khaze V, Mansoori B, Baghbani E, Baradaran B
Abstract
One of the most challenging aspects of colon cancer therapy is rapid acquisition of multidrug resistant phenotype. The multidrug resistance gene 1 (MDR1) product, p—glycoprotein (P—gp), pump out a variety of anticancer agents from the cell, giving rise to a general drug resistance against chemotherapeutic agents. The aim of this study was to investigate the effect of a specific MDR1 small interference RNA (siRNA) on sensitivity of ox...
Source: Cellular and Molecular Biology - December 2, 2015 Category: Molecular Biology Tags: Cell Mol Biol (Noisy-le-grand) Source Type: research
Down-Regulating Receptor Interacting Protein Kinase 1 (RIP1) Promotes Oxaliplatin-Induced Tca8113 Cell Apoptosis.
CONCLUSIONS Down-regulating RIP1 promotes oxaliplatin induced Tca8113 cells apoptosis.
PMID: 26460489 [PubMed - in process]
Source: Medical Science Monitor - October 16, 2015 Category: Research Tags: Med Sci Monit Source Type: research
